ClinicalTrials.gg
RecruitingNCT06421376Updated May 30, 2025

Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer

A Phase 2 interventional study of Cardonilizumab and Chemoradiotherapy ±immunotherapy in Esophageal Cancer, Immunotherapy and Induction Therapy, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Recruiting at 3 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-30.

Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Esophageal Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences — 17 open to participants now, 17 under way, 4 of them phase 3. Esophageal Neoplasms · Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

Planned enrollment
16th of 21
60 · median 120
Started
2024
with 4 others
Phase 2
9 of 22
7 open now
Primary completion
2026-12
later than 10 of 16 live
Registered
16th of 22
by date

Among the 22 studies in Esophageal Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, this one is the 16th largest by planned enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2024, is one of 9 in phase 2, reaches primary completion later than 10 of the 16 other live ones, and was the 16th registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

17 of the 22 studies in Esophageal Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences are open now, in 1 country. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Where they have run

Who these studies take

Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Esophageal Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, or all of them as a file.
02

Study summary

Although unprecedented advances have been made in the field of esophageal cancer in recent decades, the prognosis for patients with locally advanced esophageal squamous cell carcinoma (ESCC) remains extremely poor, accounting for 30-40% of overall survival at 5 year. In recent years, multimodal treatments have proven to be an appropriate therapeutic approach for locally advanced ESCC. Recently, immunotherapy developed rapidly. The purpose of this study was to observe the efficacy and safety of cardonilizumab combined with chemoradiotherapy in the treatment of locally advanced ESCC.

03

Conditions studied

  • Esophageal Cancer
  • Immunotherapy
  • Induction Therapy
  • Chemoradiotherapy
  • Surgery
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-80 years old;
  • Eligible patients were confirmed esophageal squamous cell carcinoma;
  • Eligible patients were proven locally advanced ESCC (cT1-2N1-3M0-1, cT3/T4N0-3M0-1, M1 was limited to supraclavicular lymph node )diagnosed by computed tomography [CT] and/or endoscopic ultrasonography [EUS] according to the American Joint Committee on Cancer (AJCC) 8th edition staging system;
  • PS score: 0\~1;
  • Main organs and bone marrow function are normal: routine blood tests: (Hb) ≥100g/L ; (NEUT)≥1.5×109/L; (PLT) ≥100×109/L; white blood cell (WBC)≥3.5×109/L,biochemical examination: (ALT) and aspartate aminotransferase (AST) ≤1.5×UNL; serum total (TBIL) ≤1.5×UNL; serum creatinine ( Cr) 1.0×1.5UNL, and BUN≤1.0×UNL;

Exclusion criteria

Exclusion Criteria:

  • Those combined with other primary malignant tumors other than esophageal cancer (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);
  • patients who had previously received other treatments
  • At the time of diagnosis, there were distant and hematogenous beyond the supraclavicular lymph node region, including retroperitoneal multiple lymph node metastasis, bone metastasis, , lung metastasis, liver metastasis, malignant pleural effusion and ascites
  • Those who already have esophageal perforation or are at high risk of esophageal perforation
  • Patients whose tumors invade close to large blood vessels and are at risk of bleeding in the
  • there are active infections, such as active tuberculosis and hepatitis
  • There are to immunotherapy.
  • Pregnant or lactating women and women of childbearing age do not take reliable measures
  • Combined with serious cardiovascular diseases, such as uncontrolled heart failure, coronary heart disease, cardiomyopathy, uncontrolled arrhythmia, uncontrolled hypertension, or a history of myocardial infarction within the past 6 months; and those combined with other uncontrolled acute and chronic diseases such as hypertension and diabetes.
  • Violation of inclusion and exclusion criteria, or other reasons that the researcher believes cannot continue the study of drug treatment.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Inductive chemoimmunotherapy+chemoradiotherapy±surgery

    In this group, the patients were given 2 cycles of inductive therapy of cardonilizumab combined with chemotherapy, followed by concurrent chemoradiotherapy with two cycles of nab-paclitaxel and cisplatin plus radiotherapy of 50-50.4 Gy. After clinical evaluation, surgery was feasible for a part of patients.

    Drug: Cardonilizumab · Radiation: Chemoradiotherapy ±immunotherapy · Procedure: Radical surgery

Interventions

  • DrugCardonilizumab

    Two cycles of Inductive therapy: nab-paclitaxel 250mg/ m2+cisplatin 75mg/ m2+Cardonilizumab 10mg/kg,ivgtt,3 weeks per cycle for 2 cycles

  • RadiationChemoradiotherapy ±immunotherapy

    Chemoradiotherapy ± immunotherapy: * PTV: 50-50.4Gy/1.8-2Gy/25-28fractions ②nab-paclitaxel 100mg+cisplatin 25mg/ m2, d1, every 7 days for 3-5 weeks ③Cardonilizumab 10mg/kg,ivgtt,3 weeks per cycle for 2 cycles

  • ProcedureRadical surgery

    Surgery was evaluated after concurrent chemoradiotherapy according to patients willing and the surgeons' assessment. If patients were accessed with unresectable disease after radiotherapy or refused to receive surgery, Cardonilizumab would be administered for 2 years or until disease progression.

06

What researchers measure

Primary outcomes

  1. Event-free survival

    Time from treatment initiation to locoregional or distant recurrence, or death from any cause.

    Time frame: 1-year

Secondary outcomes

  1. Overall survival

    The 1-year OS rate was defined as the proportion of patients who still alive within one year from treatment initiation.

    Time frame: 1-year

  2. Adverse events

    In terms of adverse events of radiation, chemotherapy and immunotherapy

    Time frame: 1-year

  3. Locoregional recurrence free survival

    The 1-year rate was defined as the proportion of patients who did not have any locoregional recurrence from treatment initiation.

    Time frame: 1-year

  4. Distant metastasis free survival

    The 1-year rate was defined as the proportion of patients who did not have any distant metastasis from treatment initiation.

    Time frame: 1-year

07

Study locations

1 of 3 sites recruiting
  • Anyang Cancer Hospital
    Anyang, Henan, China
    Not yet recruiting
    • Xiaomin Wang, M.D. · Contact
  • The First Affiliated Hospital of Xinxiang Medical University
    Xinxiang, Henan, China
    Not yet recruiting
    • Xiaomei Liu, M.D. · Contact
  • Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)
    Beijing, 100021, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Dec 2026, 31 months after the start.

Of 174 non-industry phase 2 interventional studies under Esophageal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 85. This study's planned 31 months is below that.

Counting every sponsor, half of 198 studies reached it within 52 months; a quarter within 33 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2024
First posted
May 20, 2024
StartActual
May 1, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
May 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06421376
Responsible party
Jianjun Qin (Principal Investigator, Cancer Institute and Hospital, Chinese Academy of Medical Sciences) — Principal investigator
First posted
May 20, 2024
Start date
May 1, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
May 30, 2025

Study contacts

Xin Wang, M.D.
Contact
beryl_wx2000@163.com
+8601087787635
Xin Wang
principal investigator · Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion